Adjudication of etiology of acute kidney injury: experience from the TRIBE-AKI multi-center study by Jay L Koyner et al.
Koyner et al. BMC Nephrology 2014, 15:105
http://www.biomedcentral.com/1471-2369/15/105RESEARCH ARTICLE Open AccessAdjudication of etiology of acute kidney injury:
experience from the TRIBE-AKI multi-center study
Jay L Koyner2, Amit X Garg4, Heather Thiessen-Philbrook4, Steven G Coca1, Lloyd G Cantley1, Aldo Peixoto1,
Cary S Passik3, Kwangik Hong1, and Chirag R Parikh1* for the TRIBE-AKI ConsortiumAbstract
Background: Adjudication of patient outcomes is a common practice in medical research and clinical trials.
However minimal data exists on the adjudication process in the setting of Acute Kidney Injury (AKI) as well as the
ability to judge different etiologies (e.g. Acute Tubular Necrosis (ATN), Pre-renal Azotemia (PRA)).
Methods: We enrolled 475 consecutive patients undergoing cardiac surgery at four sites of the Translational
Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) study. Three expert nephrologists performed
independent chart review, utilizing clinical variables and retrospective case report forms with pre intra and post-
operative data, and then adjudicated all cases of AKI (n = 67). AKI was defined as a > 50% increase in serum creatinine
for baseline (RIFLE Risk). We examined the patterns of AKI diagnoses made by the adjudication panel as well as
association of these diagnoses with pre and postoperative kidney injury biomarkers.
Results: There was poor agreement across the panel of reviewers with their adjudicated diagnoses being independent
of each other (Fleiss’ Kappa = 0.046). Based on the agreement of the two out of three reviewers, ATN was the
adjudicated diagnosis in 41 cases (61%) while PRA occurred in 13 (19%). Neither serum creatinine or any other biomarker
of AKI (urine or serum), was associated with an adjudicated diagnosis of ATN within the first 24 post-operative hours.
Conclusion: The etiology of AKI after cardiac surgery is probably multi-factorial and pure forms of AKI etiologies, such
as ATN and PRA may not exist. Biomarkers did not appear to correlate with the adjudicated etiology of AKI; however
the lack of agreement among the adjudicators impacted these results.
Trial registration: Clinicaltrials.gov: NCT00774137
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Acute Kidney Injury (AKI), regardless of the definition
employed, is a common complication following adult
cardiac surgery [1,2]. Increasing acceptance of standard-
ized definitions of AKI amongst nephrologists and inten-
sivists has advanced several aspects of AKI research yet
the practical issue of what constitutes “true AKI” clinic-
ally, remains unsettled [3-8]. Novel biomarkers have
demonstrated promising associations with AKI [3,4],
leading to a resurgence in clinical trials in the setting of* Correspondence: chirag.parikh@yale.edu
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unless otherwise stated.AKI [9]. However, given the suboptimal performance of
some biomarkers, there is only limited data to support
the role of accurate adjudication of AKI to improve the
diagnostic and discriminative performance of traditional
and modern markers of renal function [10].
Recent research has focused on augmenting serum
creatinine’s limited ability to detect true renal tubular in-
jury, rather than a temporary change in glomerular fil-
tration (pre-renal azotemia, PRA) [11-15]. Conceptually,
PRA, defined as a transient decrease in the effective per-
fusion of the kidney, either from volume depletion or
relative hypotension, should spare damage to the kid-
ney/renal tubules in comparison to other intrinsic (intra-
renal) causes of kidney injury [16,17]. Some maintain
that attempting to clinically distinguish PRA from intrin-
sic kidney injury is not feasible and likely unnecessary asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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non-cardiac surgery studies have had varying success in
attempting to adjudicate AKI events and tease out the
ability of novel biomarkers to distinguish PRA from dir-
ect tubular injury [10,14,15].
Separating PRA from intrinsic forms of AKI, including
its most severe form acute tubular necrosis (ATN), is
crucial as future clinical trials will be designed and pow-
ered to treat those with evidence of cellular kidney death
(ATN). Thus recruiting, enrolling and studying patients
with ATN is of the utmost importance, ensuring that we
are treating a cohort of patients at the highest risk for
the most severe forms of AKI and the worst clinical out-
comes. Enrolling patients who have PRA, and who will
not develop ATN will not only, increase study costs and
weaken findings but also potentially expose patients to a
therapeutic that they will not benefit from and thus in-
crease patient risk. Pragmatically, all AKI (PRA, ATN,
obstruction, athero-embolic disease and other sources)
are at their simplest defined in terms of a rise in serum
creatinine and/or a decrease in urine output, thus differ-
entiation utilizing these two traditional tools is difficult.
Compounding this dilemma, prolonged PRA may progress
across the AKI spectrum to overt ATN over a patient
specific time course. Unfortunately the pathognomonic
“muddy brown casts” of ATN are not always present early
in the course of AKI or at the time of renal consultation,
rendering ATN a diagnostic possibility even in the absence
of these clinical findings [19]. Finally, several of the other
tools (fractional excretion of sodium and urea) used to
distinguish between PRA and ATN have been shown to
be ineffective following cardiac surgery [11,20].
In this nested prospective cohort sub-study of the
Translational Research Investigating Biomarker End-
points in AKI (TRIBE AKI) study, we established a
framework for the AKI adjudication process as well as
provide adjudication outcomes in adults who developed
AKI [3]. Additionally, we investigated the association of
several AKI biomarkers (traditional and modern) with
the adjudicated AKI outcome.
Methods
Study sample
We conducted a prospective cohort sub-study of adults
undergoing cardiac surgery (coronary artery bypass graft-
ing [CABG], surgery for valve disease and both) at four
academic medical centers in North America between July
2007 and December 2009. All patients were at high risk
for AKI, defined by the presence of one or more of the fol-
lowing criteria: 1) Pre-existing renal impairment (baseline
serum creatinine > 2 mg/dL [177 μmol/L]) 2) An ejection
fraction <35% or grade 3 or 4 left ventricular dysfunction,
3) Age > 70 years, 4) History of diabetes mellitus, 5)
Scheduled to undergo a concomitant CABG and valvesurgery, or 6) Scheduled to undergo a repeat revasculari-
zation surgery.
Adult patients were excluded if they had any of the
following: 1) evidence of AKI prior to surgery (pro-
longed pre-operative surgical hospitalization with 2 or
more pre-operative creatinine values with a > 0.3 mg/dl
(26.5 μmol/L) increase), 2) prior kidney transplantation,
3) a pre-operative serum creatinine level > 4.5 mg/dL
(400 μmol/L) 4) pre-existing end-stage renal disease, 5)
administration of a nephro-toxic drug preoperatively
(except for IV contrast, angiotensin converting enzymes
inhibitors and angiotensin II receptor blockers), 6)
planned surgery for a ventricular assist device or con-
genital heart disease or 7) if they did not have one serum
creatinine test prior to the surgery in the hospital labora-
tory used by the hospital where the subject will undergo
their surgery.
All participants provided written informed consent
and the study was approved by The Institutional Review
Boards (IRB) of The University of Chicago, Yale Univer-
sity and Danbury Hospital and the University of Western
Ontario Research Ethics Board. This clinical study was
registered at Clinicaltrials.gov as NCT00774137 on
October 16, 2008 and adheres to the STROBE guidelines
for cohort studies (Additional file 1).
The primary outcome of AKI was determined by the
daily creatinine measurements during the first five hos-
pital days. AKI was defined by RIFLE “Risk” or higher:
an increase of ≥ 50% from pre-operative baseline [5].
Additionally, clinical care, including the decision to initi-
ate renal replacement therapy or other renal interven-
tions, was made by the primary service and the
Nephrology Consult service, without involvement of the
study investigators.
Pre-operative creatinine was measured as part of rou-
tine clinical care in each hospital’s clinical lab. Estimated
glomerular filtration rates (eGFR) were calculated using
the modified MDRD equation [21,22]. Serum creatinine
was collected daily during the hospital stay. Past medical
and surgical histories as well as preoperative co-morbid
conditions were obtained from the patient and the clin-
ical record, using standardized definitions of the Society
of Thoracic Surgeons (STS) data collection tool. These
included, but were not limited to variables that had been
included in the prior STS registry risk-assessment tool
for predicting AKI after cardiac surgery, as well as others
related to kidney function estimation. These included
demographics (age, sex, race), co-morbidities (hyperten-
sion, diabetes mellitus, heart failure, prior myocardial in-
farction), preoperative medication utilization and surgical
characteristics (elective or urgent; bypass, valvular surgery,
or both; prior cardiac operation). Patients requiring emer-
gent surgery were excluded from this study. Additionally,
intra-operative variables (cardio pulmonary bypass time,
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cardioplegia, intra-aortic balloon pumps, blood products,
and vaso-active medications) were also collected. Finally
post-operative factors including but not limited to daily
serum creatinine, daily urine output and fluid balance,
post-operative medication utilization (including detailed
diuretic and vaso-active medication records), post-operative
complications (prolonged intubation, re-operation, need
for blood products, length of ICU and hospital stay, mo-
dality and timing of any RRT and mortality data) were all
recorded.
Outcome definitions
All patients who developed post-operative AKI had their
entire case report form and hospital course independently
retrospectively reviewed by a panel of 3 independent aca-
demic nephrologists (SCG; LGC, AP). The committee
members were chosen on the basis of expertise in clinical
nephrology and represented individuals across a spectrum
of years in practice, and from federal and academicFigure 1 Blank adjudication form – This figure demonstrates the blan
review for those patients with AKI in the post-operative period. Adjud
AKI (PRA, ATN or Indeterminate).hospital settings. None of the adjudicators were involved
with clinical care of the patients in this study.
Retrospectively the adjudication panel individually uti-
lized de-identified case report forms, which contain all
of the aforementioned pre-, intra and post-operative data
to assign an AKI diagnosis of ATN, PRA or indetermin-
ate. Additionally, all 3 panelists were asked to complete
a checklist following their case-decision providing the
rationale behind their diagnostic decision (Figure 1). In
those cases that were indeterminate, the panelists were
required to supply the rationale for their decision. The
panelists were blinded to patient identifiers, the names/
location of the treating physicians and all data on novel
biomarkers. Finally, all panelists operated independently
and were blinded to the adjudication results of their 2
co-adjudicators. If two adjudicators agreed on any eti-
ology, then this consensus was considered to be a final
diagnosis for the patient. At the end of study, there was
an in-person meeting of the three adjudicators to discuss
the cases where no two adjudicators agreed on a givenk form that individual panelists completed after their chart
icators we asked to supply their rationale for selecting the etiology of
Table 1 Breakdown of diagnoses made via the AKI
adjudication panel
Final adjudication result* Total
n (%)Panelists adjudications ATN PRA Indeterminate
3ATN 11 11 (16)
3PRA 2 2 (3)
2ATN; 1PRA 16 16 (24)
2ATN; 1IND 11 11 (16)
2PRA; 1ATN 4 4 (6)
2PRA; 1IND 6 6 (9)
2IND; 1ATN 2 2 (3)
2IND; 1PRA 5 5 (8)
1ATN; 1PRA; 1IND 3 1 6 10 (15)
Total 41 13 13 67 (100)
ATN = Acute Tubular Necrosis, PRA = Pre-Renal Azotemia.
*Final Adjudication Result was assigned if at least 2 adjudicators agreed on the
AKI etiology. Adjudicators met in-person to reach a final consensus on the
10 cases where the initial adjudication differed across all 3 adjudicators.
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adjudicators could agree on a diagnosis.
AKI biomarker measurements
Urine IL-18 and NGAL were measured with the
ARCHITECT® assay (Abbott Diagnostics, Abbott Park,
IL). We measured urine creatinine by the modified Jaffe
reaction. We measured plasma NGAL using the Triage
NGAL immunoassay, in conjunction with the Triage
Meter (Biosite Inc., San Diego, CA) CV of 10% [3].
Urine albumin was reported as the ratio to urinary cre-
atinine (ACR) and was measured via immunoturbidime-
try on a Siemens Dimension Plus with HM clinical
analyzer per the manufacturer’s instructions [23]. BNP
was measured via the Biosite Triage meter (Biosite, San
Diego California) method [24]. KIM-1 LFABP and urine
Cystatin C were all measured via Sekisui Diagnostics
LLC developed antibody ELISA assays [25,26].
Statistical considerations
Continuous variables were compared with two-sample t-
test or Wilcoxon rank sum test and dichotomous vari-
ables with the chi-square test or Fisher’s exact test.
Fleiss’ kappa was used to determine inter-rater inde-
pendence across all 3 adjudicators while Cohen’s kappa
was used for pairs of adjudicators.
Results
We enrolled 478 of patients in this sub-study Three sub-
jects were excluded due to violations of inclusion/exclu-
sion criteria, leaving 475 subjects in the final analyses.
Sixty-seven (14%) of these individuals developed AKI,
defined by RIFLE “Risk”. Of those individuals who devel-
oped AKI, 6 (1.2% of the total, 9% of those with AKI)
went on to require RRT. Of the 67 subjects with AKI,
there was 100% agreement amongst the 3 adjudication
panelists on only 13 cases (19%). In 11 (16%) subjects,
there was complete agreement that ischemic ATN was
the cause of AKI; while PRA was the adjudicated diag-
nosis in the remaining 2 cases (3.0% of the total). In
none of the 67 cases did all 3 panelists agree that the
cause of AKI was indeterminate (Table 1).
In the 56 (81%) remaining cases of AKI there was not
a unanimous consensus; however, in 46 (69% of the
total) cases, 2 adjudicators agreed on a diagnosis. The
most common scenario was 2 reviewers diagnosing ATN
with the third diagnosing PRA (25% of the total cases); a
complete list of the adjudications can be found in
Table 1. There were 10 (14.9%) cases in which all 3 pan-
elists originally disagreed about the underlying diagnosis,
with each panelist choosing separate options; PRA, ATN
and Indeterminate. During an in-person meeting these
10 cases were eventually judged to be 1 case of PRA, 3
cases of ATN and 6 cases of indeterminate. The clinicalcharacteristics of the adjudicated sub-groups (ATN, PRA
and Indeterminate) are depicted in Table 2. Individuals
adjudicated to have ATN were more likely to have a
higher peak post-operative serum creatinine, lower urine
output during the first 48 post-operative hours and a
longer duration of AKI compared to those with PRA.
Those judged to have PRA were more likely to have pre-
operative exposure to radio-contrast.
Investigation into the diagnosis patterns of the 3 indi-
vidual adjudicators demonstrated that despite receiving
the same instruction set and diagnostic materials, there
was tremendous variability across all 3 panelists (Table 3).
The adjudications of our 3 panelists were statistically inde-
pendent of each other (Fleiss’ Kappa = 0.046). However
when looking at individual adjudicator pairings no pairing
provided a Cohen’s Kappa < 0.05. (Adjudicator 1 and 2
Cohen kappa = 0.24; Adjudicator 1 and 3 Cohen kappa =
0.06; Adjudicator 2 and 3 Cohen kappa = 0.10).
Table 4 demonstrates the mean pre and post-operative
biomarker values throughout the first 5 days for all sub-
jects adjudicated to either ATN or PRA. No biomarker
was significantly different across these 2 groups during
the first 24 post-operative hours. There was a statistical
difference between KIM-1 values at Day 2 but this effect
was not sustained over subsequent post-operative days.
Serum Creatinine and Serum Cystatin C were not statis-
tically different until Day 3 with both of these effects be-
ing sustained over the next 2 post-operative days.
Discussion
The development of AKI following cardiac surgery is ex-
tremely complex. Preoperative factors such as exposure to
nephro-toxins (e.g. radio contrast from cardiac cathe-
terization) and pre-existing conditions (congestive heart









Age (years) 72.9 (11.6) 72.5 (9.4) 75.7 (8.4) 0.68
Female sex 6 (46%) 16 (39%) 5 (39%) 0.65
BMI 30.5 (5.6) 32.3 (7.2) 29.1 (6.8) 0.51
Caucasian Race 13 (100%) 38 (93%) 11 (85%) 0.32
Diabetes Mellitus 9 (69%) 20 (49%) 4 (31%) 0.20
Baseline Serum Creatinine (mg/dL) 1.01 (0.31) 1.14 (0.38) 1.06 (0.34) 0.39
Baseline eGFR (CKD-EPI) ml/min 68.99 (18.77) 63.28 (21.95) 67.68 (21.33) 0.37
Repeat Cardiac Surgery 2 (17%) 9 (22%) 3 (23%) 0.69
Pre-op Contrast Exposure 3 (23%) 2 (4.9%) 1 (7.7%) 0.05
Intra-op Factors
Type of Surgery 0.95
CABG alone 5 (39%) 15 (37%) 9 (75%)
Valve alone 3 (23%) 11 (27%) 3 (25%)
CABG and Valve 5 (39%) 15 (37%) 0 (0%)
Off-Pump Surgery 0 (0%) 2 (5%) 3 (23%) 0.44
CPB Time (min) 103.54 (44.34) 139.03 (62.11) 117.44 (59.54) 0.07
Cross Clamp Time (min) 84 (40.66) 95.21 (44.08) 81.89 (47.01) 0.45
Post op Factors
Length of ICU stay (days) 2.38 (1.45) 12.02 (30.74) 4.38 (4.44) 0.29
Length of Hospitalization (days) 6.77 (1.92) 17.49 (32.23) 7.85 (3.65) 0.07
Received RRT 0 (0%) 6 (15%) 0 (0%) 0.14
Maximum Serum Post op Creatinine (mg/dl) 1.64 (0.55) 2.18 (0.76) 1.84 (0.58) 0.03
Absolute Increase of Maximum Serum Creatinine (mg/dL) 0.63 (0.25) 1.04 (0.55) 0.77 (0.39) 0.01
Maximum% Increase of Serum Creatinine (%) 62 (12) 96 (59) 76 (48) 0.03
Duration of AKI (Days) 1 [1, 2] 2 [1, 4] 1 [0.5, 1] 0.0002
Urine Output/Fluid Balance
Urine output 0-6 hr (mls) 1435 [1185, 2643] 1085 [890, 1395] 1015 [667, 1600] 0.04
Urine output day 2 (mls) 1916 [1151, 3200] 1030 [710, 1505] 2095 [925, 3075] 0.02
Urine output day 3 (mls) 2000 [1620, 3690] 1315 [800, 1760] 1133 [733, 1950] 0.01
Net fluid Balance 0-6 hr 1716 [665, 1961] 1488 [437, 2504] 1251 [783, 1836] 0.65
Net fluid Balance Day 2 539 [-1920, 1839] 2040 [68, 3438] 79 [-835, 2110] 0.16
Net fluid Balance Day 3 510 [-1493, 790] 225 [-386, 1532] −122 [-572, 1054] 0.43
RIFLE “I” n (%) 0 (0%) 16 (39%) 3 (23%) 0.01
RIFLE “F” n (%) 0 (0%) 4 (9.8%) 1 (7.7%) 0.24
Hospital Mortality n (%) 0 (0%) 6 (15%) 1 (7.7%) 0.16
*P-value is the result of comparison between ATN and PRA. Wilcoxon test used for continuous variables and Chi-square Test for categorical variables.







ATN, n (%) 49 (73.2) 40 (59.7) 14 (20.9)
PRA, n (%) 9 (13.4) 9 (13.4) 39 (58.2)
Indeterminate, n (%) 9 (13.4) 18 (26.9) 14 (20.9)
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ease) contribute and interact with operative factors such
as emergent surgery, intra-operative hypotension and
cardio-pulmonary bypass (CPB) pump time in determin-
ing AKI and patient outcomes. The interplay of these fac-
tors along with the patient’s post-operative course (e.g.
mechanical ventilation, use of vaso-active medications,
Table 4 Post-operative biomarker values for patients








Pre-op 34 (41) 42 (79) 0.33
Day 1 0-6 hr 74 (169) 173 (617) 0.73
Day 1 6-12 hr 328 (978) 50 (68) 0.81
Day 1 12-18 hr 85 (108) 76 (105) 0.90
Day 2 81 (79) 95 (132) 0.77
Day 3 57 (72) 91 (112) 0.17
Day 4 110 (124) 102 (110) 0.97
Day 5 60 (72) 103 (164) 0.34
Urine IL-18
Pre-op 28 (26) 63 (263.93) 0.49
Day 1 0-6 hr 68 (108) 147.13 (517.98) 0.39
Day 1 6-12 hr 249 (640) 168.01 (416.33) 0.85
Day 1 12-18 hr 77 (37) 211.72 (328.66) 0.24
Day 2 91 (55) 186.03 (298.02) 0.79
Day 3 108 (166) 103.42 (191.36) 0.72
Day 4 46 (43) 73.07 (107.88) 0.83
Day 5 25 (20) 42.79 (77.48) 0.85
Urine KIM 1
Pre-op 3.8 (6.2) 3.0 (6.7) 0.73
Day 1 0-6 hr 1.7 (2.5) 1.7 (2.6) 0.57
Day 1 6-12 hr 2.7 (3) 2.4 (1.7) 0.62
Day 2 9.1 (4.9) 5.4 (4.0) 0.01
Day 3 14.8 (9.5) 12.4 (11.7) 0.28
Day 4 9.2 (9.0) 9.0 (9.7) 0.97
Day 5 4.5 (3.4) 6.2 (8.6) 0.96
Urine LFABP
Pre-op 33 (57) 27 (86) 0.77
Day 1 0-6 hr 68 (65) 118 (156) 0.66
Day 1 6-12 hr 84 (157) 97 (141) 0.29
Day 2 63 (111) 75 (125) 0.95
Day 3 64 (116) 52 (92) 0.69
Day 4 126 (173) 98 (140) 0.71
Day 5 92 (134) 79 (126) 0.52
Urine Cystatin C
Pre-op 0.24 (0.18) 0.27 (0.39) 0.54
Day 1 0-6 hr 0.20 (0.13) 0.22 (0.13) 0.81
Day 1 6-12 hr 0.27 (0.21) 0.21 (0.13) 0.40
Day 2 0.25 (0.17) 0.26 (0.22) 0.85
Day 3 1.12 (2.65) 0.42 (0.94) 0.42
Day 4 1.94 (3.46) 0.57 (1.07) 0.63
Day 5 1.63 (3.12) 1.14 (3.22) 0.77
Table 4 Post-operative biomarker values for patients
adjudicated to PRA and ATN (Continued)
Urine Albumin
Pre-op 175 (379) 133 (287) 0.89
Day 1 0-6 hr 35 (36) 56 (109) 0.5
Day 1 6-12 hr 48 (77) 47 (55) 0.39
Day 1 12-18 hr 77 (154) 95 (143) 0.42
Day 2 72 (136) 71 (84) 0.26
Day 3 107 (168) 77 (77) 0.84
Urine ACR
Pre-op 0.27 (0.74) 0.16 (0.3) 0.94
Day 1 0-6 hr 0.21 (0.19) 0.15 (0.17) 0.32
Day 1 6-12 hr 0.11 (0.18) 0.09 (0.13) 0.64
Day 1 12-18 hr 0.07 (0.1) 0.11 (0.16) 0.45
Day 2 0.06 (0.08) 0.11 (0.14) 0.13
Day 3 0.1 (0.14) 0.08 (0.09) 0.64
Serum NGAL
Pre-op 82 (30) 99 (54) 0.43
Day 1 214 (91) 259 (90) 0.20
Day 2 213 (123) 236 (123) 0.54
Day 3 162 (68) 224 (132) 0.17
Day 4 102 (54) 184 (133) 0.04
Day 5 87 (31) 147 (86) 0.09
Serum BNP
Pre-op 152 (94) 194 (226) 0.67
Day 1 111 (118) 112 (118) 0.67
Day 2 297 (202) 337 (224) 0.50
Day 3 364 (180) 373 (219) 0.76
Day 4 525 (151) 442 (297) 0.11
Day 5 458 (209) 431 (208) 0.67
Serum Creatinine
Pre-op 0.99 (0.32) 1.14 (0.39) 0.31
Day 1 1.15 (0.45) 1.32 (0.46) 0.26
Day 2 1.53 (0.56) 1.68 (0.67) 0.5
Day 3 1.39 (0.57) 2.06 (0.72) <0.01
Day 4 1.21 (0.4) 1.88 (0.67) <0.01
Day 5 1.1 (0.33) 1.66 (0.58) <0.01
Serum Cystatin C
Pre-op 0.92 (0.29) 1.13 (0.4) 0.13
Day 1 0.86 (0.27) 1.02 (0.31) 0.12
Day 2 1.04 (0.47) 1.26 (0.43) 0.11
Day 3 1.08 (0.34) 1.54 (0.52) <0.01
Day 4 0.99 (0.26) 1.62 (0.52) <0.01
Day 5 1.02 (0.27) 1.49 (0.51) 0.01
(All values Mean (SD)).
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http://www.biomedcentral.com/1471-2369/15/105balloon pumps or diuretics) all may contribute to the de-
velopment of AKI. As such determining the etiology of
AKI while relying on the clinical course and changes in
serum creatinine and urine output is therefore often a
subjective and challenging task. As AKI research moves
into an era of clinical trials, it will be increasingly import-
ant to ensure that all subjects enrolled with AKI have a
similar etiology of renal dysfunction as interventions
aimed at ischemia-induced ATN may not work in nephro-
toxin or contrast related injury, let alone in the setting of
functional PRA. Just as previous interventions have failed,
in part, because they were initiated too late, future agents
may not work if they are investigated across a broad
spectrum of AKI [27]. Our initial experiences with the ad-
judication of cardiac surgery associated AKI demonstrate
that while feasible, this process is not perfect.
It is extremely important that clinical definitions of
AKI are harmonized beyond a simple elevation in serum
creatinine or decrease in urine output. Our experience
demonstrates that not all AKI following cardiac surgery
is the same and that a clean, precise, one-hit phenotype
likely does not exist. In the past cardiac surgery associ-
ated AKI was thought to be a homogenous clinical entity
predominantly due to renal ischemia-reperfusion injury
however over the last decade investigators have recog-
nized that it is a multi-factorial process that involves
ischemia-reperfusion, inflammation, variation systemic
hemodynamics, athero-embolic disease and nephrotox-
ins [28,29]. With so many factors to consider it is not
surprising that there was a large degree of variation in
the adjudicated diagnoses across our 3 panelists with all
3 adjudicators agreeing only 19% of the time. Their dis-
crepant clinical decision making when possessing identi-
cal information is readily apparent in Table 3. In the
end, 41 (61%) subjects were judged to have ATN while
13 (19%) had PRA with several of these cases requiring
an in-person discussion in order to arrive at a final diag-
nosis. It is important to reiterate that the evaluation
process was done retrospectively months after the
hospitalization and that all three reviewers had access to
the same clinical information, but not the novel bio-
markers data. Thus, at most, only 60% of AKI subjects
would have been appropriate for enrollment in a thera-
peutic study to treat or diminish the effects of ATN.
This is an important issue, as future trials will seek to
identify cohorts in the early post-operative period who
are at risk for ATN while attempting to minimize the
enrollment of those with functional forms of AKI. In
our study, differences in glomerular filtration markers
(Serum Creatinine and Cystatin C) were not apparent
until post-operative day 3 (Table 4). Such a timeframe
is likely outside of the therapeutic window for many
novel treatments that require early access to the injured
nephron. Relying solely on serum creatinine kineticstherefore is not a viable option for achieving diagnostic
distinction.
Not surprisingly, given the poor agreement across our
3 adjudicators, no biomarker, consistently distinguished
etiology of AKI within the first 48 post-operative hours.
While there is limited data to support the notion that
novel biomarkers have the ability to discriminate ATN
from PRA [14,15,30]; our data does not corroborate this,
but must be interpreted in light of the lack of consensus
amongst the adjudicators. In the past it has been argued
that elevation of urinary markers of renal tubular injury
with concomitant increased in serum creatinine would
indicate true ATN; however, given our inter-rater vari-
ability, we could not verify this [17]. Importantly, some
of these past studies used specific time parameters to
differentiate PRA from ATN while our adjudicators
where free to determine a diagnosis regardless of AKI
duration. However, despite this difference our ATN
cases were of a significantly greater duration compared
to PRA. While biomarkers were not included in our ad-
judication process, we endorse the idea that future re-
search should investigate the utility of biomarkers in
distinguishing ATN from other types of kidney injury in
a variety of clinical settings.
As nephrologists advance AKI clinical research and re-
engage the idea of prophylactic and therapeutic inter-
ventional trials we need to 1) recognize that while
cardiac surgery produces a reliable rate of AKI, not all
elevations in serum creatinine are pathophysiologically
equivalent and 2) develop a reliable and consistent sys-
tem to adjudicate AKI patient diagnoses. It would be un-
founded to assume that individuals with PRA have the
same risks (short and long term) as those with ATN; yet
the published literature often lumps these two clinical
entities together to encompass changes in serum creatin-
ine [5,6]. For decades cardiologists, intensivists and on-
cologists have refined their ability to define patient
diagnoses, yet to date there has been little movement on
this issue in the field of AKI. More recently clinical adju-
dication has begun to be relevant and appeared in the
AKI literature [10,14,15,30]. However, in these few cases
the AKI in question was diverse and the adjudication
sought to identify those subjects with PRA in order to
determine how well novel biomarkers correlated with
AKI outcomes. Additionally, these studies measured bio-
markers at the time of clinical AKI or time of peak
serum creatinine and our study measured biomarkers in
the early post-operative period which may help explain
the lack of association in our study.
Our study was limited in that we could only adjudicate
67 cases of AKI. Additionally, our adjudication process
was limited by the lack of urinalysis microscopy data.
We recommend that future studies should attempt to
include some element of urine sediment analysis as
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protocol driven allowing for inter-study comparison
[31-33]. However, microscopy remains a user dependent
tool that displays a tremendous amount of inter-
physician variability [34]. Wald and colleagues demon-
strated that despite the importance of urinalysis in the
diagnosis of renal injury, nephrologists generally achieve
only fair to moderate levels of agreement in the identifi-
cation of important structures on urinalysis and that
agreement between nephrologists was not enhanced
based on their level of experience. Thus the inclusion of
microscopy may have only further muddied our adjudi-
cation process given that the pathognomonic “muddy
brown casts” are not always present at the time of mi-
croscopy even in cases of a known diagnosis of ATN
[19]. Additionally, had microscopy been included in the
early post-operative period (e.g. ICU arrival), it’s utility
remains unclear as there is no published data on the
ability of urine microscopy to predict patient outcomes
following adult cardiac surgery.
For the past decade several other branches of medicine
have succeeded in formalizing the process of patient
event adjudication and utilized the results to help fur-
ther medical research. Over the next decade, adjudica-
tion of AKI events will be crucial during the data
collection and event analysis of both interventional and
prophylactic AKI trials. Our study demonstrates that
while adjudication is technically feasible, the interpret-
ation of clinical data in the setting of cardiac surgery re-
mains a challenge. Our experiences, while not perfect,
will hopefully provide the building blocks of a formalized
process that will allow for inter-study comparison of
AKI events. Once a standardized format for adjudication
is in place, the role of novel biomarkers in this process
can be explored but, currently, such a role remains in-
cipient. Further work is needed to ensure that in the set-
ting of AKI following cardiac surgery, one nephrologist’s
PRA is not another nephrologist’s ATN. Until the cap-
acity to produce unified descriptions/definitions is in
place, we are instead left with a definition of cardiac sur-
gery associated ATN that is extremely subjective.
Conclusions
In this nested prospective cohort sub-study of the TRIBE
AKI study 56% of those with AKI were adjudicated to
have ATN (by at least 2 of the 3 reviewers). Demonstrat-
ing that over one-third of patients with AKI may not de-
rive a benefit from interventions aimed at treating or
repair tubular injury. Our experiences have led us to
conclude that the etiology of AKI after cardiac surgery is
multi-factorial and pure AKI etiologies, such as ATN
and PRA may not exist. In our study biomarkers did not
correlate with the adjudicated etiology of AKI; however
the lack of agreement among the adjudicators impactedthese results. Further investigation and formalization of
the AKI adjudication process, and its interaction with
AKI biomarkers, is needed in order to ensure equality in
AKI etiologies in future critical care nephrology clinical
trials.
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